Bisphosphonate prodrugs utilizing endogenous carriers

Targeting of therapeutic agents to a specific site, as well as controlling the rate and time of release, has been intensively investigated and established over the last decades. These studies concerning drug delivery systems led to the formulation of several products that can improve the diffusion a...

Full description

Bibliographic Details
Main Author: Giammei, Carolina
Other Authors: Matemaattis-luonnontieteellinen tiedekunta, Faculty of Sciences, Kemian laitos, Department of Chemistry, University of Jyväskylä, Jyväskylän yliopisto
Format: Master's thesis
Language:eng
Published: 2016
Subjects:
Online Access: https://jyx.jyu.fi/handle/123456789/51889
_version_ 1826225766340231168
author Giammei, Carolina
author2 Matemaattis-luonnontieteellinen tiedekunta Faculty of Sciences Kemian laitos Department of Chemistry University of Jyväskylä Jyväskylän yliopisto
author_facet Giammei, Carolina Matemaattis-luonnontieteellinen tiedekunta Faculty of Sciences Kemian laitos Department of Chemistry University of Jyväskylä Jyväskylän yliopisto Giammei, Carolina Matemaattis-luonnontieteellinen tiedekunta Faculty of Sciences Kemian laitos Department of Chemistry University of Jyväskylä Jyväskylän yliopisto
author_sort Giammei, Carolina
datasource_str_mv jyx
description Targeting of therapeutic agents to a specific site, as well as controlling the rate and time of release, has been intensively investigated and established over the last decades. These studies concerning drug delivery systems led to the formulation of several products that can improve the diffusion across the barriers after drug administration. For this purpose, the development of strategies of novel drug delivery systems for bisphosphonates had taken hold to improve both the bioavailability and safety. Firstly, they have been used for over a century in the branch of industry and later, in the 1960s, in medicine. Bisphosphonates are synthetic compound analogs to the naturally occurring pyrophosphates. They are characterized by two phosphate groups bound to the same carbon atom, a ‘P-C-P’ moiety, and two functional groups R1 and R2. Mainly, bisphosphonates are effective inhibitors of bone resorption due to calcium disorders, such as osteoporosis, Paget’s disease, hypercalcemia of malignancy, multiple myeloma, and bone metastasis. Generally, they can be classified into two groups according to their mechanism of action: non-nitrogen containing bisphosphonates and nitrogen containing bisphosphonates. However, the therapeutic use of bisphosphonates is restricted by their poor oral bioavailability (less than 1%) due either to their hydrophilic properties and to the bulky and charged phosphonate groups. In order to overcome these issues and enhance the intestinal permeability of bisphosphonates, a prodrug design approach has been evaluated for these compounds. In the literature review of this thesis an overview of some of the available synthetic strategies, which involve the modification of the functional groups with a bioreversible promoiety according to the desired properties in the compound, is presented. The experimental part is aimed to conjugate bisphosphonates with bile acids in order to improve the oral bioavailability of the bisphosphonate. To optimize the yield, three different synthetic strategies were tested. In all syntheses sodium alendronate was used as the bisphosphonate and deoxycholic acid as the bile acid.
first_indexed 2023-03-22T10:00:23Z
format Pro gradu
free_online_boolean 1
fullrecord [{"key": "dc.contributor.advisor", "value": "Siev\u00e4nen, Elina", "language": "", "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.author", "value": "Giammei, Carolina", "language": null, "element": "contributor", "qualifier": "author", "schema": "dc"}, {"key": "dc.date.accessioned", "value": "2016-11-15T12:42:39Z", "language": "", "element": "date", "qualifier": "accessioned", "schema": "dc"}, {"key": "dc.date.available", "value": "2016-11-15T12:42:39Z", "language": "", "element": "date", "qualifier": "available", "schema": "dc"}, {"key": "dc.date.issued", "value": "2016", "language": null, "element": "date", "qualifier": "issued", "schema": "dc"}, {"key": "dc.identifier.other", "value": "oai:jykdok.linneanet.fi:1643057", "language": null, "element": "identifier", "qualifier": "other", "schema": "dc"}, {"key": "dc.identifier.uri", "value": "https://jyx.jyu.fi/handle/123456789/51889", "language": "", "element": "identifier", "qualifier": "uri", "schema": "dc"}, {"key": "dc.description.abstract", "value": "Targeting of therapeutic agents to a specific site, as well as controlling the rate and time of release, has been intensively investigated and established over the last decades. These studies concerning drug delivery systems led to the formulation of several products that can improve the diffusion across the barriers after drug administration. \r\nFor this purpose, the development of strategies of novel drug delivery systems for bisphosphonates had taken hold to improve both the bioavailability and safety. Firstly, they have been used for over a century in the branch of industry and later, in the 1960s, in medicine. Bisphosphonates are synthetic compound analogs to the naturally occurring pyrophosphates. They are characterized by two phosphate groups bound to the same carbon atom, a \u2018P-C-P\u2019 moiety, and two functional groups R1 and R2. Mainly, bisphosphonates are effective inhibitors of bone resorption due to calcium disorders, such as osteoporosis, Paget\u2019s disease, hypercalcemia of malignancy, multiple myeloma, and bone metastasis. Generally, they can be classified into two groups according to their mechanism of action: non-nitrogen containing bisphosphonates and nitrogen containing bisphosphonates. \r\nHowever, the therapeutic use of bisphosphonates is restricted by their poor oral bioavailability (less than 1%) due either to their hydrophilic properties and to the bulky and charged phosphonate groups. In order to overcome these issues and enhance the intestinal permeability of bisphosphonates, a prodrug design approach has been evaluated for these compounds. In the literature review of this thesis an overview of some of the available synthetic strategies, which involve the modification of the functional groups with a bioreversible promoiety according to the desired properties in the compound, is presented. \r\nThe experimental part is aimed to conjugate bisphosphonates with bile acids in order to improve the oral bioavailability of the bisphosphonate. To optimize the yield, three different synthetic strategies were tested. In all syntheses sodium alendronate was used as the bisphosphonate and deoxycholic acid as the bile acid.", "language": "en", "element": "description", "qualifier": "abstract", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Submitted using Plone Publishing form by Carolina Giammei (cagiamme) on 2016-11-15 12:42:38.688058. Form: Master's Thesis publishing form (https://kirjasto.jyu.fi/publish-and-buy/publishing-forms/masters-thesis-publishing-form). JyX data: [jyx_publishing-allowed (fi) =True]", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Submitted by jyx lomake-julkaisija (jyx-julkaisija.group@korppi.jyu.fi) on 2016-11-15T12:42:39Z\r\nNo. of bitstreams: 2\r\nURN:NBN:fi:jyu-201611154628.pdf: 3222066 bytes, checksum: f4f0ba9a5aa6502c90b853987d72f3c9 (MD5)\r\nlicense.html: 4278 bytes, checksum: 61d7097529a0141576c3b05001bd5d05 (MD5)", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Made available in DSpace on 2016-11-15T12:42:39Z (GMT). No. of bitstreams: 2\r\nURN:NBN:fi:jyu-201611154628.pdf: 3222066 bytes, checksum: f4f0ba9a5aa6502c90b853987d72f3c9 (MD5)\r\nlicense.html: 4278 bytes, checksum: 61d7097529a0141576c3b05001bd5d05 (MD5)\r\n Previous issue date: 2016", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.format.extent", "value": "1 verkkoaineisto (77 sivua)", "language": null, "element": "format", "qualifier": "extent", "schema": "dc"}, {"key": "dc.format.mimetype", "value": "application/pdf", "language": null, "element": "format", "qualifier": "mimetype", "schema": "dc"}, {"key": "dc.language.iso", "value": "eng", "language": null, "element": "language", "qualifier": "iso", "schema": "dc"}, {"key": "dc.rights", "value": "In Copyright", "language": "en", "element": "rights", "qualifier": null, "schema": "dc"}, {"key": "dc.subject.other", "value": "Drug Delivery Systems", "language": null, "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "Prodrugs", "language": null, "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "Bisphosphonates", "language": null, "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "Bile acids", "language": null, "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "Organic chemistry", "language": null, "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.title", "value": "Bisphosphonate prodrugs utilizing endogenous carriers", "language": null, "element": "title", "qualifier": null, "schema": "dc"}, {"key": "dc.type", "value": "master thesis", "language": null, "element": "type", "qualifier": null, "schema": "dc"}, {"key": "dc.identifier.urn", "value": "URN:NBN:fi:jyu-201611154628", "language": null, "element": "identifier", "qualifier": "urn", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Pro gradu -tutkielma", "language": "fi", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Master\u2019s thesis", "language": "en", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Matemaattis-luonnontieteellinen tiedekunta", "language": "fi", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Faculty of Sciences", "language": "en", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Kemian laitos", "language": "fi", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Department of Chemistry", "language": "en", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "University of Jyv\u00e4skyl\u00e4", "language": "en", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "Jyv\u00e4skyl\u00e4n yliopisto", "language": "fi", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Orgaaninen kemia", "language": "fi", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Organic Chemistry", "language": "en", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "dc.date.updated", "value": "2016-11-15T12:42:40Z", "language": "", "element": "date", "qualifier": "updated", "schema": "dc"}, {"key": "yvv.contractresearch.funding", "value": "0", "language": "", "element": "contractresearch", "qualifier": "funding", "schema": "yvv"}, {"key": "dc.type.coar", "value": "http://purl.org/coar/resource_type/c_bdcc", "language": null, "element": "type", "qualifier": "coar", "schema": "dc"}, {"key": "dc.rights.accesslevel", "value": "openAccess", "language": "fi", "element": "rights", "qualifier": "accesslevel", "schema": "dc"}, {"key": "dc.type.publication", "value": "masterThesis", "language": null, "element": "type", "qualifier": "publication", "schema": "dc"}, {"key": "dc.subject.oppiainekoodi", "value": "4035", "language": null, "element": "subject", "qualifier": "oppiainekoodi", "schema": "dc"}, {"key": "dc.subject.yso", "value": "bisfosfonaatit", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.format.content", "value": "fulltext", "language": null, "element": "format", "qualifier": "content", "schema": "dc"}, {"key": "dc.rights.url", "value": "https://rightsstatements.org/page/InC/1.0/", "language": null, "element": "rights", "qualifier": "url", "schema": "dc"}, {"key": "dc.type.okm", "value": "G2", "language": null, "element": "type", "qualifier": "okm", "schema": "dc"}]
id jyx.123456789_51889
language eng
last_indexed 2025-02-18T10:55:59Z
main_date 2016-01-01T00:00:00Z
main_date_str 2016
online_boolean 1
online_urls_str_mv {"url":"https:\/\/jyx.jyu.fi\/bitstreams\/d7dc2594-b413-414f-9ad4-2a99fba0ece0\/download","text":"URN:NBN:fi:jyu-201611154628.pdf","source":"jyx","mediaType":"application\/pdf"}
publishDate 2016
record_format qdc
source_str_mv jyx
spellingShingle Giammei, Carolina Bisphosphonate prodrugs utilizing endogenous carriers Drug Delivery Systems Prodrugs Bisphosphonates Bile acids Organic chemistry Orgaaninen kemia Organic Chemistry 4035 bisfosfonaatit
title Bisphosphonate prodrugs utilizing endogenous carriers
title_full Bisphosphonate prodrugs utilizing endogenous carriers
title_fullStr Bisphosphonate prodrugs utilizing endogenous carriers Bisphosphonate prodrugs utilizing endogenous carriers
title_full_unstemmed Bisphosphonate prodrugs utilizing endogenous carriers Bisphosphonate prodrugs utilizing endogenous carriers
title_short Bisphosphonate prodrugs utilizing endogenous carriers
title_sort bisphosphonate prodrugs utilizing endogenous carriers
title_txtP Bisphosphonate prodrugs utilizing endogenous carriers
topic Drug Delivery Systems Prodrugs Bisphosphonates Bile acids Organic chemistry Orgaaninen kemia Organic Chemistry 4035 bisfosfonaatit
topic_facet 4035 Bile acids Bisphosphonates Drug Delivery Systems Orgaaninen kemia Organic Chemistry Organic chemistry Prodrugs bisfosfonaatit
url https://jyx.jyu.fi/handle/123456789/51889 http://www.urn.fi/URN:NBN:fi:jyu-201611154628
work_keys_str_mv AT giammeicarolina bisphosphonateprodrugsutilizingendogenouscarriers